三级aa视频在线观看-三级国产-三级国产精品一区二区-三级国产三级在线-三级国产在线

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Sanofi targets ground-breaking therapies with a new R&D strategy

chinadaily.com.cn | Updated: 2022-03-31 11:04
Share
Share - WeChat
John Reed, executive vice-president, global head of research and development at Sanofi. [Photo provided to chinadaily.com.cn]

"We are sharpening our R&D focus on first-in-class or best-in-class medicines and vaccines in order to address the world's most urgent healthcare needs", said John Reed, executive vice-president and head of Global R&D of Sanofi. He emphasized Sanofi's scientific mission when talking about the company's R&D strategy, "because patients are counting on us."

Reed, formerly the head of Roche Pharma Research and Early Development (pRED), joined Sanofi in 2018, where he participated in and witnessed a crucial strategic transformation of the company.

As an essential step in Sanofi's "Play to Win" strategy, announced in 2019, the company launched a new brand identity and purpose to highlight its corporate mission "Chase the miracles of science to improve people's lives" early this year.

Companies that implement rebranding will often make key strategic adjustments, and Sanofi is no exception. As an R&D-driven pharmaceutical company, Sanofi has made the transformation of its R&D strategy central to its rebranding initiatives.

"The pursuit of scientific miracles is a dynamic process, and the process of R&D is challenging, but we don't let the setbacks deter us from pushing forward and working to improve the lives of patients," Reed said.

A new transformation, a new ambition

Founded in 1973, Sanofi is a young global pharmaceutical company. In the past several decades, it has developed many breakthrough therapies, including Lantus (insulin glargine), Taxotere (anti-cancer drug), Lovenox (anti-coagulant), Aubagio (multiple sclerosis), and Cerezyme (Gaucher disease).

For almost half a century, Sanofi has been protecting lives with its vaccines, saving and transforming lives with its cutting-edge science, from primary care to the treatment of cancer and rare diseases. It took Sanofi only 32 years to go from being a small company to being one of the top pharmaceutical giants in the world, an astonishingly rapid ascent compared with century-old pharmaceutical companies.

Despite such extraordinary past achievements, Sanofi is reflecting on the most urgent healthcare needs which have yet to be resolved. Can innovation and R&D be refocused? Can products have greater clinical value? How to sustain long-term growth? According to Reed, Sanofi has strictly prioritized and reallocated resources for R&D.

Based on its expertise and experience with preventing and treating conditions from chronic diseases to rare diseases, Sanofi further optimizes resources to sharpen its R&D focus to first-in-class or best-in-class programs in vaccines and specialty care areas like immunology and oncology, where recent breakthroughs open up a world of new therapeutic opportunities.

A sign of Sanofi's progress is that in 2021 it added 36 phase I and phase II clinical development programs, a clear indication of its strong pipeline of early-stage projects. The company is also investing more in biologics – seen in the fact that they now represent over 70 percent of its pipeline.

According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has been approved for treating moderate-to-severe atopic dermatitis, Fitusiran and Efanesoctocog alfa (BIVV001) for treatment of hemophilia, Amlitelimab for treatment of inflammatory disorders, Amcenestrant for treatment of breast cancer, RSV Vaccine Nirsevimab, and Tolebrutinib for treatment of multiple sclerosis.

Sanofi's changes are also evident in its financial performance. In the newly released 2021 annual financial report, specialty medicine has become Sanofi's most prominent business unit by sales for the first time, with R&D investment in specialty drug products accounting for 95 percent of the company's total R&D investment, up by about 50 percent from that of 2017.

1 2 3 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 欧美精品国产一区二区三区 | 欧美日韩在线播放一区二区三区 | 张柏芝国产www | 在线欧美精品二区三区 | 国产大陆xxxx做受视频 | 精品欧美一区二区三区在线观看 | 成人av在线播放 | 亚洲高清不卡视频 | 小明永久2015xxx免费看视频 | 国产麻豆高清在线观看 | 韩国一级黄色毛片 | 在线看污片 | 精品国产福利在线观看91啪 | 日本黄网站| 国自产精品手机在线视频香蕉 | 国产视频一二 | 精品日韩欧美国产一区二区 | 五月天激激婷婷大综合丁香 | 日本伊人网 | 99免费精品 | 俄罗斯一级成人毛片 | 中文字幕卡二和卡三的视频 | 精品亚洲成a人在线播放 | 操大逼视频| 日韩免费看片 | 国产精品美女在线观看 | 三级黄色大片 | 日本一区二区三区久久精品 | 日本与大黑人xxxx | 国产黄色一级网站 | 小明明看看视频永久免费网 | 97视频免费观看2区 97午夜 | 免费黄色视屏 | 国产视频久久久 | 黄色一级录像 | 午夜国产视频 | 一品道一本香蕉视频 | 国产成人综合亚洲一区 | 日本精品中文字幕有码 | 欧美激情片网站 | 国产欧美日韩中文久久 |